✦ LIBER ✦

Defining rewardable innovation in drug therapy

✍ Scribed by Aronson, Jeffrey K.; Ferner, Robin E.; Hughes, Dyfrig A.

Book ID: 121657697
Publisher: Nature Publishing Group
Year: 2012
Tongue: English
Weight: 123 KB
Volume: 11
Category: Article
ISSN: 1474-1776
DOI: 10.1038/nrd3715

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Defining “Innovativeness” in Drug Develo

Defining “Innovativeness” in Drug Development: A Systematic Review

✍ Kesselheim, A S; Wang, B; Avorn, J 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 469 KB

EPMA rewards innovation in PM

📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 594 KB

Compulsive use of dopaminergic drug ther

Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti-reward

✍ Andrew H. Evans; Andrew D. Lawrence; Silke Appel Cresswell; Regina Katzenschlage 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

A few Parkinson patients develop a disabling pattern of compulsive dopaminergic drug use (''dopamine dysregulation syndrome''-DDS). DDS patients commonly identify aversive dysphoric ''OFF'' mood-states as a primary motivation to compulsively use their drugs. We compared motoric, affective, nonmotor

Is Drug Innovation Still Rewarded in the

Is Drug Innovation Still Rewarded in the Top 5 European Pharmaceutial Markets?

✍ Reinaud, F.; Ando, G. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

Defining the clinical role of pharmacoge

Defining the clinical role of pharmacogenetics in antiepileptic drug therapy

✍ Dlugos, D J; Buono, R J; Ferraro, T N 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 50 KB

Defining ‘Surveillance’ in Drug Safety

✍ Dr Jeffrey K. Aronson, Manfred Hauben, Andrew Bate 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 185 KB